Trials / Completed
CompletedNCT03979248
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
An Open-Label, Single-Sequence Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole on the Pharmacokinetics of BMS-986165 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of stomach acid suppression by rabeprazole and BMS-986165 on how fast and complete the drug is absorbed into the body of healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days. |
| DRUG | Rabeprazole | Specified dose on specified days. |
Timeline
- Start date
- 2019-05-16
- Primary completion
- 2019-07-07
- Completion
- 2019-07-07
- First posted
- 2019-06-07
- Last updated
- 2020-11-02
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03979248. Inclusion in this directory is not an endorsement.